Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study.
Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. JAMA Ophthalmol. 2017 06 01; 135(6):654-656.
View in:
PubMed
subject areas
Angiogenesis Inhibitors
Angiogenesis Inhibitors
Bevacizumab
Bevacizumab
Dose-Response Relationship, Drug
Dose-Response Relationship, Drug
Female
Female
Gestational Age
Gestational Age
Humans
Humans
Infant, Newborn
Infant, Newborn
Intravitreal Injections
Intravitreal Injections
Male
Male
Retinopathy of Prematurity
Retinopathy of Prematurity
Treatment Outcome
Treatment Outcome
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor A
authors with profiles
Raymond M Siatkowski